DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Carcinoma, Renal Cell

Interventions: Drug: combination of gemcitabine, capecitabine, and bevacizumab

First Posted Date: 2007-08-31

Last Posted Date: 2014-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 30

Registration Number: NCT00523640

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Gefitinib

First Posted Date: 2007-08-21

Last Posted Date: 2016-07-01

Lead Sponsor: University of Chicago

Target Recruit Count: 44

Registration Number: NCT00519077

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

Family Therapy for Adolescent Bulimia Nervosa

Phase 2

Completed

Conditions: Bulimia Nervosa

Interventions: Behavioral: FBT-BN
Behavioral: SPT

First Posted Date: 2007-08-21

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 80

Registration Number: NCT00518843

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: carboplatin
Drug: bevacizumab

First Posted Date: 2007-08-16

Last Posted Date: 2014-04-15

Lead Sponsor: University of Chicago

Target Recruit Count: 11

Registration Number: NCT00517361

Locations: 🇺🇸
Oncology Specialists, Park Ridge, Illinois, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Inhaled Nitric Oxide and Neuroprotection in Premature Infants

Phase 2

Terminated

Conditions: Periventricular Leukomalacia
Prematurity
Bronchopulmonary Dysplasia
Intraventricular Hemorrhage

Interventions: Drug: inhaled nitric oxide
Drug: oxygen

First Posted Date: 2007-08-13

Last Posted Date: 2024-10-17

Lead Sponsor: University of Chicago

Target Recruit Count: 273

Registration Number: NCT00515281

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: AndroGel
Drug: placebo

First Posted Date: 2007-08-13

Last Posted Date: 2014-06-11

Lead Sponsor: University of Chicago

Target Recruit Count: 6

Registration Number: NCT00515112

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 8 locations

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Biological: 4-peptide melanoma vaccine
Drug: Ontak

First Posted Date: 2007-08-13

Last Posted Date: 2021-01-26

Lead Sponsor: University of Chicago

Target Recruit Count: 17

Registration Number: NCT00515528

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Explanted Lung Tissues With Pulmonary Fibrosis

Recruiting

Conditions: Pulmonary Fibrosis

First Posted Date: 2007-08-13

Last Posted Date: 2024-12-20

Lead Sponsor: University of Chicago

Target Recruit Count: 90

Registration Number: NCT00515567

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation

Phase 2

Completed

Conditions: Neurotic Excoriation
Pathologic Skin Picking
Dermatillomania
Psychogenic Excoriation

Interventions: Drug: Lamictal (lamotrigine)
Drug: Placebo

First Posted Date: 2007-08-08

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 35

Registration Number: NCT00513019

Locations: 🇺🇸
Ambulatory Research Center, Minneapolis, Minnesota, United States

Transfer to Another Health Care Facility Following Critical Illness

Completed

Conditions: Transfer to a Health Care Facility After Critical Illness

First Posted Date: 2007-06-11

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 548

Registration Number: NCT00484445

Locations: 🇺🇸
University of Chicago Hospitals, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy